+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Cancer Drugs Market - Global Forecast 2026-2032- Product Image
Liver Cancer Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Liver Cancer Drugs Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4896742
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Liver Cancer Drugs Market is projected to reach USD 4.49 Billion in 2026. It is expected to continue growing at a CAGR of 5.92%, reaching USD 6.36 Billion by 2032.

Primary liver cancer remains one of oncology’s highest-urgency treatment areas. According to IARC GLOBOCAN 2022, liver cancer accounted for approximately 866,000 new cases and 759,000 deaths worldwide, ranking among the leading causes of cancer mortality. Hepatocellular carcinoma represents the majority of cases, while cholangiocarcinoma and other rare liver malignancies add clinically complex, high-need segments.

The liver cancer drugs landscape is being reshaped by immune checkpoint inhibitors, anti-VEGF combinations, tyrosine kinase inhibitors, and biomarker-directed therapies. Demand is supported by high unmet need, chronic hepatitis B and C burden, rising metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, and expanding use of systemic therapy in advanced hepatocellular carcinoma treatment.

Transformative Shifts in Liver Cancer Treatment

The treatment landscape has moved beyond single-agent sorafenib toward combination immunotherapy, targeted therapy sequencing, and multidisciplinary care. Atezolizumab plus bevacizumab and durvalumab plus tremelimumab have changed first-line standards for eligible unresectable hepatocellular carcinoma patients, while lenvatinib, regorafenib, cabozantinib, ramucirumab, and immunotherapy options continue to support later-line strategies.

Commercial success increasingly depends on evidence generation across overall survival, progression-free survival, quality of life, safety in cirrhotic populations, biomarker selection, and real-world effectiveness. Drug developers are also expanding into adjuvant, neoadjuvant, locoregional-combination, and earlier-stage settings where recurrence risk after resection or ablation remains substantial.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across liver cancer drug discovery, clinical development, and care delivery. AI-enabled imaging analytics, radiomics, digital pathology, and electronic health record mining are being used to identify high-risk patients, refine trial eligibility, support earlier detection of disease progression, and evaluate treatment response more consistently.

For manufacturers, AI can improve target discovery, molecule screening, trial site selection, patient recruitment, adverse event monitoring, and real-world evidence generation. The greatest near-term impact is expected where AI tools are prospectively validated, integrated with clinician workflows, and aligned with regulatory expectations for transparency, bias control, data quality, and clinical utility.

Regional Insights Across the Liver Cancer Drugs Market

Asia-Pacific represents the largest epidemiological opportunity for liver cancer drugs because hepatitis B prevalence, population scale, and established regional disease burden drive substantial incidence, with China contributing a major share of global cases reported by IARC. Japan, South Korea, Australia, India, and ASEAN markets are expanding adoption of immunotherapy and targeted therapies, although reimbursement depth, screening coverage, and specialist access vary widely across public and private healthcare systems.

North America remains a high-value region due to broad access to FDA-approved systemic therapies, strong guideline adoption, advanced oncology infrastructure, and significant clinical trial activity. Europe benefits from EMA approvals, national health technology assessment systems, and mature liver disease networks, but reimbursement timing and evidence thresholds differ across major economies. Latin America shows growing demand in Brazil and Mexico, while affordability, diagnostic delays, and public-sector access remain constraints. The Middle East is investing in tertiary oncology centers, particularly across the GCC, and Africa faces the greatest access gap despite meaningful viral hepatitis, aflatoxin exposure, and late-stage disease burden.

Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN demand is shaped by hepatitis B-related liver cancer, uneven screening coverage, variable reimbursement, and accelerating private-sector oncology investment in major urban centers. The GCC is characterized by rising specialist capacity, public healthcare investment, and demand for innovative oncology therapies, particularly as national cancer strategies strengthen diagnosis, referral pathways, and tertiary treatment access.

The European Union emphasizes comparative clinical benefit, budget impact, and health technology assessment discipline, making robust survival, safety, and quality-of-life evidence essential for liver cancer drug adoption. BRICS countries combine high patient volume, local manufacturing ambitions, and strong pricing pressure, creating opportunities for differentiated originators, biosimilars, generics, and access partnerships. G7 markets remain central to premium launch sequencing, guideline influence, and clinical trial leadership, while NATO member countries overlap with many advanced regulatory and supply-chain environments where resilience, pharmacovigilance, secure distribution, and continuity of oncology care are increasingly important.

Country Insights for Strategic Market Prioritization

The United States is a leading commercial environment for liver cancer drugs due to rapid FDA uptake, specialist networks, broad clinical trial activity, and established use of immunotherapy combinations in eligible patients. Canada offers structured provincial reimbursement and guideline-led adoption, while Mexico and Brazil present large patient pools with persistent access differences between private and public systems and rising demand for advanced hepatocellular carcinoma treatment.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are important launch markets shaped by NICE, AMNOG, HAS, AIFA, and national reimbursement frameworks that scrutinize clinical benefit, safety, and economic value. Russia remains clinically relevant but is affected by procurement, access, and geopolitical complexity. China is critical because of its liver cancer burden, hepatitis B prevalence, expanding domestic oncology innovation, and growing use of immuno-oncology regimens. India combines high unmet need with affordability constraints and uneven specialist access, Japan and South Korea have advanced oncology adoption supported by strong hospital infrastructure, and Australia provides guideline-based access with a comparatively smaller population base.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated combination strategies, biomarker-informed development, and evidence packages that address cirrhosis, bleeding risk, liver function, viral etiology, and real-world tolerability. Trial designs should include globally representative populations, viral and non-viral etiologies, diverse liver function profiles, and endpoints that reflect both survival and patient experience.

Market access teams should build early health economic models, plan companion diagnostics where relevant, and pursue partnerships that improve screening, referral, treatment initiation, and continuity of care. Organizations competing in liver cancer drugs should also strengthen pharmacovigilance, physician education, patient support, and supply reliability across emerging markets where late diagnosis and access limitations remain major barriers.

Research Methodology

This executive summary is based on triangulated secondary and primary research. Core inputs include WHO and IARC GLOBOCAN cancer statistics, FDA and EMA approval records, ClinicalTrials.gov, peer-reviewed oncology journals, and treatment guidelines from organizations such as NCCN, ESMO, AASLD, and ASCO.

Market interpretation was developed by assessing epidemiology, therapy adoption, clinical trial pipelines, reimbursement environments, regulatory pathways, competitive positioning, and regional access dynamics. Findings were validated through cross-source comparison and expert interpretation to ensure that conclusions are evidence-based, commercially relevant, and suitable for strategic planning without relying on market sizing or forecasting.

Conclusion and Strategic Outlook

The liver cancer drugs landscape is entering a more competitive and evidence-intensive era. Immunotherapy combinations have raised the standard of care, targeted therapies continue to support sequencing strategies, and AI is strengthening discovery, trial execution, clinical workflow integration, and real-world evidence generation.

Sustained progress will depend on earlier diagnosis, broader access, rational combinations, biomarker development, and proof of value across diverse healthcare systems. Organizations that align scientific innovation with affordability, safety, and measurable patient outcomes will be best positioned to lead in hepatocellular carcinoma treatment and the broader liver cancer therapeutics landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Liver Cancer Drugs Market, by Therapy Type
7.1. Introduction
7.2. Chemotherapy
7.3. Immunotherapy
7.4. Radiation Therapy
7.5. Targeted Therapy
8. Liver Cancer Drugs Market, by Cancer Type
8.1. Introduction
8.2. Cholangiocarcinoma
8.3. Hepatoblastoma
8.4. Hepatocellular Carcinoma (HCC)
9. Liver Cancer Drugs Market, by Administration Route
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Liver Cancer Drugs Market, by Drug Class
10.1. Introduction
10.2. Cytotoxic Agents
10.3. Monoclonal Antibodies
10.4. Tyrosine Kinase Inhibitors (TKIs)
11. Liver Cancer Drugs Market, by End User
11.1. Introduction
11.2. Home Care
11.3. Hospital
11.4. Specialty Clinic
12. Liver Cancer Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Liver Cancer Drugs Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Liver Cancer Drugs Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Liver Cancer Drugs Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Agenus Inc.
17.3. Alnylam Pharmaceuticals, Inc.
17.4. Astellas Pharma Inc.
17.5. AstraZeneca PLC
17.6. Bayer AG
17.7. BeiGene, Ltd.
17.8. Bristol-Myers Squibb Company
17.9. C. H. Boehringer Sohn AG & Co. KG
17.10. Can-Fite BioPharma Ltd.
17.11. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
17.12. CStone Pharmaceuticals
17.13. Eisai Co., Ltd.
17.14. Eli Lilly and Company
17.15. Exelixis, Inc.
17.16. F. Hoffmann-La Roche Ltd.
17.17. Genfit S.A.
17.18. Gilead Sciences, Inc.
17.19. GlaxoSmithKline plc
17.20. Innovent Biologics, Inc.
17.21. Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
17.22. Ipsen SA
17.23. Jiangsu Hengrui Medicine Co., Ltd.
17.24. Johnson & Johnson Services Inc.
17.25. Merck & Co., Inc.
17.26. Moderna, Inc.
17.27. Novartis AG
17.28. Pfizer Inc.
17.29. Sanofi SA
17.30. Takeda Pharmaceutical Company Limited
17.31. Vertex Pharmaceuticals Incorporated
17.32. Zai Lab Limited
List of Figures
FIGURE 1. GLOBAL LIVER CANCER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL LIVER CANCER DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL LIVER CANCER DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL LIVER CANCER DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL LIVER CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL RADIATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL RADIATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL RADIATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL HEPATOBLASTOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL HEPATOBLASTOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL HEPATOBLASTOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL HEPATOCELLULAR CARCINOMA (HCC) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL HEPATOCELLULAR CARCINOMA (HCC) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL HEPATOCELLULAR CARCINOMA (HCC) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CYTOTOXIC AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CYTOTOXIC AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CYTOTOXIC AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 74. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 76. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 77. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 78. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 79. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 80. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 81. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 83. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 84. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 85. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 86. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 87. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 88. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 90. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 91. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 92. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 93. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 94. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 95. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 97. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 98. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 99. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 100. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 101. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 102. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 104. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 105. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 106. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 107. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 108. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. NATO LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. NATO LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 112. NATO LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 113. NATO LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 114. NATO LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 115. NATO LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 116. NATO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 117. G7 LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. G7 LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 119. G7 LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 120. G7 LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 121. G7 LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 122. G7 LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 123. G7 LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 124. BRICS LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. BRICS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 126. BRICS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 127. BRICS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 128. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 129. BRICS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 130. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 138. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 140. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 141. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 142. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 143. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 145. GCC LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. GCC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 147. GCC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 148. GCC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 149. GCC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 150. GCC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. GCC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 153. CHINA LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 154. CHINA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 155. CHINA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 156. CHINA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 157. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 158. CHINA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 159. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 160. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 161. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 162. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 163. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 164. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 165. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 166. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 167. JAPAN LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 168. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 169. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 170. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 171. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 172. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 174. INDIA LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 175. INDIA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 176. INDIA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 177. INDIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 178. INDIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 179. INDIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. INDIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 181. GERMANY LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 182. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 183. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 184. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 185. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 186. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 188. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 189. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 190. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 191. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 192. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 193. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 194. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 195. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 196. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 197. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 198. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 199. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 200. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 202. FRANCE LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 203. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 204. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 205. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 206. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 207. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 209. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 210. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 211. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 212. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 213. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 214. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 216. ITALY LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 217. ITALY LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 218. ITALY LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 219. ITALY LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 220. ITALY LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 221. ITALY LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. ITALY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 223. CANADA LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 224. CANADA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 225. CANADA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 226. CANADA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 227. CANADA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 228. CANADA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. CANADA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 230. RUSSIA LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 231. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 232. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 233. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 234. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 235. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 237. BRAZIL LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 238. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 239. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 240. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 241. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 242. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 244. MEXICO LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 245. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 246. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 247. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 248. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 249. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 250. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 251. SPAIN LIVER CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 252. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 253. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 254. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 255. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 256. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 257. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 258. GLOBAL LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 259. GLOBAL LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • AbbVie Inc.
  • Agenus Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • C. H. Boehringer Sohn AG & Co. KG
  • Can-Fite BioPharma Ltd.
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • CStone Pharmaceuticals
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genfit S.A.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Innovent Biologics, Inc.
  • Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
  • Ipsen SA
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
  • Zai Lab Limited

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.49 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.36 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028 - Product Image

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028

  • Report
  • 88 Pages
  • United States
From
Liver Cancer Therapeutics - Global Strategic Business Report - Product Image

Liver Cancer Therapeutics - Global Strategic Business Report

  • Report
  • 287 Pages
  • Global
From
Unresectable Hepatocellular Carcinoma Market - Global Forecast 2026-2032 - Product Image

Unresectable Hepatocellular Carcinoma Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Cancer Drugs Market - Global Forecast 2026-2032 - Product Image

Cancer Drugs Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Liver Cancer Drug Market Report 2026 - Product Image

Liver Cancer Drug Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Liver Cancer Drugs Market

The Liver Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat liver cancer. These drugs are used to reduce the size of tumors, reduce symptoms, and improve the quality of life for those affected by the disease. Commonly used drugs include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy is a type of drug that works by killing cancer cells. Targeted therapy is a type of drug that works by targeting specific molecules in cancer cells. Immunotherapy is a type of drug that works by stimulating the body's own immune system to fight cancer. The Liver Cancer Drugs market is highly competitive, with many companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly developing new drugs and treatments to improve the quality of life for those affected by liver cancer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.